Device Trial Radar · NCT04559334
Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Actual
Start
Dec 21, 2020
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Boston Children's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- SterileCare Inc.
- First posted
- Sep 22, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 3 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this research study we want to learn more about a study drug, tetrasodium sodium EDTA (Kitelock™) for maintaining the patency (blood flow) through a central venous catheter. Catheter occlusions such as blood clots have been shown to increase the risk of central line-associated bloodstream infection (CLABSI). This treatment consists of instilling a daily a dose of a solution , similar to heparin or saline lock flushes, into the catheter when it is not in use. The aim is to prevent CLABSI without increasing complications such as catheter breakage.
Conditions
- Central Line Complication
- Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Tetrasodium EDTA Catheter Lock SolutionDevice
KiteLock™ 4% Sterile Catheter Lock Solution is a single use, clear, colorless and sterile solution. It is free of preservatives, alcohol and latex and is non-pyrogenic. KiteLock™ 4% is an aqueous solution containing a mixture of edetate tetrasodium and edetate trisodium. The solution composition is equivalent to 28 mg/mL edetate. EDTA is a known chelator. This means it has an affinity for metals and elements such as calcium. As a primary mechanism of action, it acts as a space occupying solution to prevent blood from entering the tip of the catheter when the catheter is not in use. As a secondary mechanism of action, it acts as an in vitro anticoagulant. This dual action decreases the risk of clot formation, consequently thrombolytic occlusions and by extension decreases the risk of CLABSI.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Central Venous Catheter Occlusion Events During Tetrasodium EDTA Lock TherapyTime frame: 24 months before treatment initiation and 24 months after treatment initiation.
- Number of Central Venous Catheter Breakage Events During Tetrasodium EDTA Lock TherapyTime frame: 24 months before treatment initiation and 24 months after treatment initiation.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Childrens's Hospital Boston
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.